JP2013515020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515020A5 JP2013515020A5 JP2012545092A JP2012545092A JP2013515020A5 JP 2013515020 A5 JP2013515020 A5 JP 2013515020A5 JP 2012545092 A JP2012545092 A JP 2012545092A JP 2012545092 A JP2012545092 A JP 2012545092A JP 2013515020 A5 JP2013515020 A5 JP 2013515020A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- esters
- polyoxypropylene
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 150000004665 fatty acids Chemical class 0.000 claims 5
- 239000006184 cosolvent Substances 0.000 claims 4
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 150000005215 alkyl ethers Chemical class 0.000 claims 3
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims 3
- 229960002882 calcipotriol Drugs 0.000 claims 3
- 239000003961 penetration enhancing agent Substances 0.000 claims 3
- 239000011877 solvent mixture Substances 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- -1 fatty acid ester Chemical class 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 239000002085 irritant Substances 0.000 claims 2
- 229920002545 silicone oil Polymers 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 2
- 229940005605 valeric acid Drugs 0.000 claims 2
- 239000001993 wax Substances 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 claims 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940056318 ceteth-20 Drugs 0.000 claims 1
- 229960005233 cineole Drugs 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940086555 cyclomethicone Drugs 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 238000004817 gas chromatography Methods 0.000 claims 1
- 125000005908 glyceryl ester group Chemical group 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940093629 isopropyl isostearate Drugs 0.000 claims 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 1
- 229960002202 lornoxicam Drugs 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 claims 1
- PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 claims 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK2009000264 | 2009-12-22 | ||
| DKPCT/DK2009/000264 | 2009-12-22 | ||
| US29310810P | 2010-01-07 | 2010-01-07 | |
| US61/293,108 | 2010-01-07 | ||
| PCT/DK2010/000184 WO2011076209A2 (en) | 2009-12-22 | 2010-12-22 | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515020A JP2013515020A (ja) | 2013-05-02 |
| JP2013515020A5 true JP2013515020A5 (enExample) | 2013-12-19 |
| JP5732471B2 JP5732471B2 (ja) | 2015-06-10 |
Family
ID=43618136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545092A Expired - Fee Related JP5732471B2 (ja) | 2009-12-22 | 2010-12-22 | 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130023501A1 (enExample) |
| EP (1) | EP2515866B1 (enExample) |
| JP (1) | JP5732471B2 (enExample) |
| CN (1) | CN102770121B (enExample) |
| AU (1) | AU2010335656B2 (enExample) |
| BR (1) | BR112012015437A2 (enExample) |
| CA (1) | CA2785254A1 (enExample) |
| ES (1) | ES2452872T3 (enExample) |
| IL (1) | IL220517A (enExample) |
| MX (1) | MX2012007225A (enExample) |
| NZ (1) | NZ601001A (enExample) |
| RU (1) | RU2559084C2 (enExample) |
| WO (1) | WO2011076209A2 (enExample) |
| ZA (1) | ZA201204622B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186350A1 (en) * | 2013-02-27 | 2014-09-04 | Argenta Innovation Limited | Transdermal formulations |
| KR102486797B1 (ko) * | 2016-03-09 | 2023-01-11 | 삼성전자 주식회사 | 전자 장치 및 전자 장치의 디스플레이 구동 방법 |
| CN107643354B (zh) * | 2016-07-22 | 2022-02-01 | 重庆华邦胜凯制药有限公司 | 卡泊三醇起始原料a及相关杂质的分离与测定方法 |
| CN106265485A (zh) * | 2016-08-22 | 2017-01-04 | 江苏知原药业有限公司 | 一种稳定性改善的卡泊三醇组合物 |
| CN106265511A (zh) * | 2016-08-22 | 2017-01-04 | 江苏知原药业有限公司 | 一种性能优异的卡泊三醇倍他米松自微乳制剂 |
| CN108904445A (zh) * | 2018-08-06 | 2018-11-30 | 江苏知原药业有限公司 | 钙泊三醇纳米悬浮液 |
| AU2020370872A1 (en) * | 2019-10-25 | 2022-04-21 | Cardiol Therapeutics Inc. | Cannabidiol compositions for use in treating heart conditions |
| IL300006A (en) | 2020-07-28 | 2023-03-01 | Arcutis Biotherapeutics Inc | A formulation for external use containing a JAK inhibitor and Orat-4 |
| JP2024544404A (ja) | 2021-12-15 | 2024-11-29 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | Ｓｈｒ０３０２の安定な製剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4083974A (en) * | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| DE4011682A1 (de) * | 1990-04-06 | 1991-10-10 | Schering Ag | 24-oxa-derivate in der vitamin d-reihe |
| US5194431A (en) * | 1992-07-08 | 1993-03-16 | Wisconsin Alumni Research Foundation | 24-cyclopropane vitamin D derivatives |
| US5763426A (en) | 1993-01-15 | 1998-06-09 | Leo Pharmaceutical Products Ltd. | Crystalline form of a vitamin D analogue |
| GB9611603D0 (en) * | 1996-06-04 | 1996-08-07 | Leo Pharm Prod Ltd | Chemical compounds |
| US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| SI3146969T1 (en) * | 1999-04-23 | 2018-08-31 | Leo Pharma A/S | Ointment for topical treatment of psoriasis |
| US20030191093A1 (en) * | 2001-12-03 | 2003-10-09 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| ZA200510137B (en) | 2003-07-24 | 2007-04-25 | Leo Pharma As | Novel aminobenzophenone compounds |
| US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| FR2871694B1 (fr) * | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises |
| JP5015005B2 (ja) | 2004-12-13 | 2012-08-29 | レオ ファーマ アクティーゼルスカブ | トリアゾール置換アミノベンゾフェノン化合物 |
| FR2887150B1 (fr) * | 2005-06-17 | 2007-08-03 | Galderma Res & Dev | Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise |
| FR2909284B1 (fr) * | 2006-11-30 | 2012-09-21 | Galderma Sa | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien |
| KR101507717B1 (ko) | 2006-12-22 | 2015-04-08 | 레오 파마 에이/에스 | Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논 |
| JP5501770B2 (ja) | 2007-02-28 | 2014-05-28 | レオ ファーマ アクティーゼルスカブ | 新規ホスホジエステラーゼ阻害剤 |
| US7909624B2 (en) | 2007-03-26 | 2011-03-22 | Belkin International, Inc. | Carabiner universal serial bus hub |
| CA2688670A1 (en) | 2007-04-19 | 2008-10-30 | Leo Pharma A/S | Src family kinase inhibitors |
| PT2148661E (pt) * | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| WO2008141078A1 (en) | 2007-05-11 | 2008-11-20 | Sonneborn Inc. | Petrolatums having silicone-like properties |
| BRPI0922452A2 (pt) | 2008-12-19 | 2015-12-15 | Leo Pharma As | composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos. |
-
2010
- 2010-12-22 US US13/518,314 patent/US20130023501A1/en not_active Abandoned
- 2010-12-22 CN CN201080064576.4A patent/CN102770121B/zh not_active Expired - Fee Related
- 2010-12-22 EP EP10803219.4A patent/EP2515866B1/en active Active
- 2010-12-22 BR BR112012015437A patent/BR112012015437A2/pt not_active IP Right Cessation
- 2010-12-22 MX MX2012007225A patent/MX2012007225A/es active IP Right Grant
- 2010-12-22 CA CA2785254A patent/CA2785254A1/en not_active Abandoned
- 2010-12-22 AU AU2010335656A patent/AU2010335656B2/en not_active Ceased
- 2010-12-22 RU RU2012130411/15A patent/RU2559084C2/ru not_active IP Right Cessation
- 2010-12-22 JP JP2012545092A patent/JP5732471B2/ja not_active Expired - Fee Related
- 2010-12-22 NZ NZ601001A patent/NZ601001A/en not_active IP Right Cessation
- 2010-12-22 ES ES10803219.4T patent/ES2452872T3/es active Active
- 2010-12-22 WO PCT/DK2010/000184 patent/WO2011076209A2/en not_active Ceased
-
2012
- 2012-06-19 IL IL220517A patent/IL220517A/en not_active IP Right Cessation
- 2012-06-21 ZA ZA2012/04622A patent/ZA201204622B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515020A5 (enExample) | ||
| RU2012130411A (ru) | Фармацевтическая композиция, включающая растворяющую смесь и производное или аналог витамина d | |
| JP2013515018A5 (enExample) | ||
| RU2012130421A (ru) | Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ | |
| JP2013508296A5 (enExample) | ||
| JP2015527386A5 (enExample) | ||
| RU2013100996A (ru) | Композиция фармацевтического аэрозоля, включающая аналог витамина d и кортикостероид | |
| JP2015521995A5 (enExample) | ||
| JP2010521442A5 (enExample) | ||
| JP2015521996A5 (enExample) | ||
| JP2015520235A5 (enExample) | ||
| BRPI1015120B8 (pt) | Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico | |
| JP2016537339A (ja) | ホスファチジルコリンを含む噴霧可能な局部用キャリアー及び組成物 | |
| RU2015103911A (ru) | Композиция для местного применения, содержащая пленкообразующий полимер, для доставки активного ингредиента на кожу | |
| JP2013523694A5 (enExample) | ||
| JP6810201B2 (ja) | 炎症性疾患用皮膚外用組成物 | |
| JP2018526351A (ja) | Ｎｓａｉｄのための固溶体組成物 | |
| TW201444553A (zh) | 外用醫藥組成物 | |
| RU2017111503A (ru) | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| JP2022544894A (ja) | セチル化脂肪酸を含む組成物及びその関節炎及び炎症性関節症状の治療における使用 | |
| RU2012130412A (ru) | Нанокристаллы кальципотриола моногидрита | |
| JP2022545143A (ja) | セチル化脂肪酸を含む組成物を製造する方法 | |
| HRP20130237T1 (hr) | Formulacije inekalcitola | |
| JP2008532967A5 (enExample) | ||
| RU2005132004A (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен |